WO2005009475A1 - クロストリジウム属菌由来成分を含む医薬製剤 - Google Patents
クロストリジウム属菌由来成分を含む医薬製剤 Download PDFInfo
- Publication number
- WO2005009475A1 WO2005009475A1 PCT/JP2004/010395 JP2004010395W WO2005009475A1 WO 2005009475 A1 WO2005009475 A1 WO 2005009475A1 JP 2004010395 W JP2004010395 W JP 2004010395W WO 2005009475 A1 WO2005009475 A1 WO 2005009475A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- clostridium
- toxin
- derived
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a pharmaceutical preparation comprising a clostridium bacterium-derived component together with a drug. More specifically, the present invention relates to bioactive proteins and bioactive polypeptides that are difficult to cross the epithelial cell nodules of living organisms or that are difficult to transport to epithelial cells.
- a pharmaceutical preparation suitable for oral administration, transdermal administration, nasal administration or inhalation administration of drugs such as peptide, medium and low molecular weight drugs, preferably non-toxic, produced by Clostridium botulinum
- the present invention relates to a pharmaceutical preparation containing a botulinum neurotoxin complex, a hemagglutination active substance, a component thereof, or a fragment of the component.
- the present invention relates to a method for administering a drug using a component derived from the genus Clostridium.
- High molecular weight drugs composed of polypeptides or proteins such as insulin, growth hormone, and erythropoietin are decomposed by gastric acid, the action of proteolytic enzymes in the digestive tract such as the small intestine and large intestine, and the epithelium of the digestive tract.
- it is often administered by injection because it cannot be administered orally because it cannot cross the cell noria.
- medium- and low-molecular-weight drugs with high water solubility or hydrophilicity are difficult to cross the epithelial cell noria and are difficult to administer orally, and are administered by injection.
- Non-patent Document 1 Non-patent Document 2
- Non-patent Document 2 Liposo A method of encapsulating and administering the drug
- Botulinum neurotoxin the causative agent of this food poisoning, is divided into seven types, G and A, due to differences in antigenicity.
- Botulinum neurotoxin is a heat-resistant protein (7S toxin with a molecular weight of approximately 150 kDa).
- Non-patent document 3 Non-patent document 4
- Botulinum neurotoxins are also known to have therapeutic effects on strabismus, blepharospasm, unilateral facial spasm, dystonia, etc.
- Non-Patent Document 2 Biol. Pharma. Bull. 19, 1055, 1996)
- Non-Patent Document 3 Brain 21, Vol.5, No.4, 2002, 53 (389)
- Non-Patent Document 4 Protein Nucleic Acid Enzyme Vol.42, No.13 23 (1997)
- An object of the present invention is to provide a pharmaceutical preparation for oral administration, transdermal administration, nasal administration, or inhalation administration of a drug such as a polypeptide or protein, using a clostridium genus-derived component such as botulinum neurotoxin. Is to provide. Furthermore, the present invention is to provide a method for administering a drug using a component derived from the genus Clostridium.
- the inventor of the present invention has studied botulinum neurotoxin (7S toxin), a protein with a molecular weight of 150 kDa, in the course of research aimed at elucidating the mechanism of gastrointestinal epithelial cell barrier passage during food poisoning.
- botulinum neurotoxin complex produced by Clostridium botulinum and the hemagglutinating active substance (sometimes abbreviated as Free hemagglutinin, Free-HA) have the effect of significantly reducing the noria function of epithelial cells.
- the present invention is a pharmaceutical preparation containing a clostridium bacterium-derived component together with a drug.
- the present invention is a pharmaceutical preparation containing an ingredient derived from the genus Clostridium as an active ingredient, which is for delivering a drug into the body or for transporting the drug to living cells.
- the present invention is a method for administering a drug, wherein the drug is administered to a mammal including a human together with a clostridium bacterium-derived component together with the drug.
- Components derived from the genus Clostridium such as the borulinum neurotoxin complex produced by Clostridium botulinum, the hemagglutination active substance, or these components, reduce the barrier function of epithelial cells in the body and cause the drug to epithelial. It has the function of crossing the cell barrier and delivering it to the body. Therefore, by using these detoxified substances together with physiologically active proteins and physiologically active polypeptides, these drugs can be delivered to the body or transported to cells of the living body. It can be administered orally, transdermally, nasally or by inhalation.
- a Clostridium genus-derived component is used together with a drug.
- a component derived from Clostridium sp. It has the function of reducing the Noria function of the epithelial cells in the living body and delivering the drug to the body across the epithelial cell barrier, or the function of transporting the drug to the epithelial cells of the living body.
- Any component may be used. Examples include components produced by Clostridium botulinum, Clostridium difficile, Clostridium perfringens, and the like. Among these, a component derived from Clostridium borinus is preferred.
- a detoxified botulinum neurotoxin complex produced by Clostridium botulinum a hemagglutination active substance, and their structures. Examples thereof include a component, a fragment of the component, or a complex thereof.
- Botulinum neurotoxins produced by Clostridium botulinum have seven types, A to G due to antigenic differences, and botulinum neurotoxins are heat-resistant proteins (7S toxin) with a molecular weight of approximately 150 kDa.
- non-patent literature 3 and non-patent literature 4
- a botulinum neurotoxin complex in which the botulinum neurotoxin and a nontoxic component are preferably used is used.
- the 16S toxin protein nucleic acid enzyme Vol.42, No.13, 23 (1997)) produced by botulinum type A, B or C is particularly preferred.
- Botulinum type A or B 16S toxin has a molecular weight of about 500 kDa and has neurotoxin activity, hemagglutination activity, and latatoses binding activity.
- botulinum type A or B 16S toxin is a botulinum neurotoxin (7S toxin, molecular weight of about 160 kDa), non-toxic non-hemagglutinin abbreviation NTNH (nontoxic non-hemagglutinin), molecular weight of about 130 kDa) and HA with hemagglutinating activity (abbreviation of hemagglutinin, consisting of four subcomponents: HA1, HA2, HA3a, HA3b, molecular weight of about 150 kDa) is a stable complex protein bound by non-covalent bonds.
- Botulinum type A or B type 16S toxin can be easily obtained by known methods (Infection and Immunity, 71,
- Type A 19S toxin has exactly the same components as type A 16S toxin and is considered to be almost a dimer of type A 16S toxin and purified by known methods (Infection and
- Botulinum type B 16 nontoxic component and type A HA positive progenitor toxin are also preferable.
- Botulinum type B 16 nontoxic component is a non-toxic component of the nerve component and non-toxic component that dissociates B type 16S toxin at pH 8.0, and is a complex of NTNH and HA. Infection and Immunity, Mar. 2003, 1599 The product is purified by the method described in -1603.
- Type A HA positive progenitor toxin is a mixture of 16S toxin and 19S toxin among 12S toxin, 16S toxin, and 19S toxin produced by type A bacteria and purified by known methods (Infectio and Immunity, (May 1996, 1589-1594)
- these botulinum neurotoxin complexes are detoxified.
- the detoxification can be easily carried out by removing 7S toxin, which is a toxin component present in the botulinum neurotoxin complex, or treating the 7S toxin to eliminate toxicity.
- the botulinum neurotoxin complex can be separated into 7S toxin, which is a neurotoxic part, and a nontoxic component in a phosphate buffer at pH 8, and separating and purifying the nontoxic part using, for example, a ratatoose column. If necessary, the mixed neurotoxin can be removed with an anti-neurotoxin antibody.
- hemagglutinin active substance produced by Clostridium botulinum type A, B or C that is, HA having hemagglutination activity (abbreviation of hemagglutinin, HA1, HA2, HA3a, HA3b 4 (Protein Nucleic Acid Enzyme Vol.42, No.13, 23 (1997)) 0
- hemagglutination active substance produced by Borinus A or B Is preferred.
- the hemagglutination activity substance has hemagglutination activity and latatose binding activity, but has no toxicity such as lethal activity.
- the hemagglutination active substance is present alone in the culture medium of the fungus and can be purified from the culture supernatant by cation exchange chromatography and affinity column chromatography using ratatoose gel.
- the hemagglutinating active substance produced by Clostridium botulinum is not toxic and therefore does not need to be detoxified. However, if necessary, it may be subjected to detoxification treatment as described above.
- the above-described botulinum neurotoxin complex or hemagglutination active substance component, a fragment of the component, or a complex thereof can also be used.
- these components or fragments thereof are toxic, they can be detoxified by the same method as described above.
- the components of the botulinum neurotoxin complex include NTNH and HA (Infection and Immunity, Mar. 2003, p. 1599-1603; Infection and Immunity, May 1996, May, which are components of the botulinum A or B type 16S toxin.
- the constituents of the hemagglutination active substance include HA1, HA2, HA3, HA3a, HA3b and the like.
- the drug used in the present invention may be any and is not particularly limited. Drugs that are difficult to administer nasally are suitable subjects. Examples of such drugs include bioactive proteins or bioactive polypeptides having a molecular weight of about 100 kDa to 500 kDa.
- physiologically active proteins or physiologically active peptides include hormones such as insulin, growth hormone, and prolatatin; site forces such as interferon, interleukin, and tumor necrosis factor; erythropoietin, Hematopoietic factors such as mouth-priming factor; neurotransmitters such as serotonin; growth factors such as fibroblast growth factor (FGF), nerve cell growth factor (NGF), bone growth factor (BMP); urokinase, kallikrein, etc.
- a polypeptide antibiotic such as polymyxin; an analgesic polypeptide such as enkephalin; an antibody such as a polyclonal antibody, a monoclonal antibody, or a chimeric antibody.
- a drug that may be a medium-low molecular weight drug a drug having high water solubility or high hydrophilicity is a suitable target, and examples thereof include an antitumor agent such as adriamycin, 5Fu, and methotrexate. It is done.
- the pharmaceutical preparation of the present invention can be administered by oral administration, transdermal administration, nasal administration, inhalation administration and the like.
- the dosage forms for administration by these administration routes include, for example, drugs and Clostridium genus-derived components, such as detoxified botulinum neurotoxin complex, erythrocyte agglutinating active substances, these components, or components thereof
- Ingredient fragments and the like are encapsulated in liposomes or microcapsules and formulated into oral preparations, transdermal preparations, nasal preparations, and inhalation preparations.
- Ribosomes are lipid vesicles that have a bilayer membrane formed by hydration with phospholipid-based lipids and a sufficient amount of water. They are divided into multilamellar ribosomes (MLV) and single membrane liposomes. Force to be classified Any ribosome may be used in the present invention. Specifically, for example, lipids such as lecithin, sterol, phosphatidylcholine, and phosphatidylserine are solubilized with an organic solvent such as ethanol, and the solvent is removed under reduced pressure to form a membrane lipid.
- MLV multilamellar ribosomes
- aqueous solution containing a drug such as a polypeptide or protein is added thereto, and the mixture is stirred at a high speed to obtain a ribosome suspension.
- the obtained suspension can be used in the form of tablets, granules, powders, capsules and the like by conventional methods after liquid suspension or lyophilization to obtain a preparation for oral administration.
- it can be formed into ointments, creams, patch-type preparations and the like by conventional methods and used for transdermal administration.
- it can be made into a preparation for nasal administration by molding into a spray or spray by a usual method.
- it can be formed into a powder, granule, liquid, etc., filled into a capsule, and inhaled for administration by inhalation device.
- microcapsules include microvesicles in which a drug and a Clostridium bacterium-derived component are dispersed in a biodegradable synthetic polymer such as poly (d, l-lactide coderlicolide). Is mentioned.
- a biodegradable synthetic polymer is dissolved in an organic solvent such as methylene chloride, and a drug and a clostridium-derived component such as a detoxified botulinum neurotoxin complex, erythrocyte aggregation Add an aqueous solution containing the active substance, these components, or fragments of these components, stir at high speed, co-emulsify, then add a non-dissolving solvent to the biodegradable synthetic polymer to And can be obtained by adding a stabilizer and removing the solvent.
- an organic solvent such as methylene chloride
- a drug and a clostridium-derived component such as a detoxified botulinum neurotoxin complex, erythrocyte aggregation
- microcapsules thus obtained can be formed into tablets, condyles, powders, capsules and the like by conventional methods to obtain a preparation for oral administration.
- it is formed into an ointment, cream, patch type preparation, etc. by a normal method to be a preparation for transdermal administration.
- it is formed into a spray, a spray, etc. by a normal method, and is administered nasally. It can also be used as a pharmaceutical preparation.
- it can be made into a preparation for inhalation administration by a usual method.
- a drug and, for example, a detoxified botulinum neurotoxin complex, a hemagglutination active substance, a component thereof, or a fragment thereof may be used as hydroxypropylmethylcellulose powder. It can also be mixed into a powder formulation.
- An enteric preparation such as a glaze coated with an enteric polymer can also be prepared for oral administration.
- a Clostridium-derived bacterium-derived component and a drug can be added to physiological saline or the like as a solution or as a normal gel to obtain a preparation for transdermal administration or a preparation for nasal administration.
- the drug in the case of a medium-low molecular weight drug, the drug can be covalently bound to a Clostridial genus-derived component by an ordinary method.
- a fusion protein or fusion polypeptide fused with a natural component can be produced by genetic engineering and used in the present invention. In this case, it is preferable to administer the ribosome or microcapsule as described above.
- the drug and the Clostridium bacterium-derived component can be formulated separately, and each can be administered substantially simultaneously.
- the preparation containing a Clostridium genus-derived component is a pharmaceutical preparation of the present invention containing the Clostridium genus-derived component as an active ingredient, for delivering the drug into the body, or the drug in vivo. It corresponds to a pharmaceutical preparation for transporting to other cells. Even when the drug and the clostridium-derived component are formulated separately, the same formulation as described above can be formulated by the same method.
- the amount of the Clostridium bacterium-derived component varies depending on the drug used, the route of administration, etc., but is usually 0.01 to 10% by weight, preferably 0.1 to 5%, based on the drug. % By weight.
- preservatives, stabilizers, surfactants, preservatives and the like which are usually used in pharmaceutical preparations can be appropriately added as necessary.
- a protein produced by Clostridium botulinum type B bacteria having a molecular weight of about 500 kDa, having neurotoxin activity, hemagglutination activity, and ratatose binding activity.
- Type B Free-HA It is a protein produced by Clostridium botulinum type B bacteria. It has hemagglutination and ratatoses binding activity but has no lethal activity. It is present as a free-HA alone in fungal cultures. In Free-HA, as shown in Fig. 2, there are at least four subcomponents A, B, C, and D, and all or some of them are considered to form a complex. The fraction containing these subcomponents is the absorption enhancer of the present invention. Clostridium botulinum type B lamanna strain was cultured for 14 days with 14 L of external liquid by the dialysis tube culture method, and the solution in the tube was collected to obtain a culture supernatant.
- the 60% ammonium sulfate precipitate of the culture supernatant was dissolved in 50 mM phosphate buffer, dialyzed with the same solution, treated with 2% protamine, and dialyzed against 50 mM sodium acetate buffer (pH 4.2). .
- This sample was dissolved in 50 mM phosphate buffer, dialyzed with the same solution, treated with 2% protamine, and dialyzed against 50 mM sodium acetate buffer (pH 4.2). .
- T84 cells are cultured in transwell (Coaster, 4.7 cm 2 ) and maintained for about 3 weeks Thus, a tight junction between cells was formed, and a barrier for intestinal epithelial cells was constructed. Tight junction formation was determined by measuring the intercellular electrical resistance (TER).
- TER intercellular electrical resistance
- botulinum type B 16S toxin, type B 7S toxin, and type B Free-HA were added to a final concentration of 50 nM each. Then CO incubation at 37
- the cells were cultured for the time indicated on the horizontal axis in one plate, and the electrical resistance was measured. Obtained there The value obtained by subtracting the electrical resistance value of a well without cells was calculated as TER at that time. The results are shown in FIG. The vertical axis shows the TER value at each time in%, with the TER value immediately before the addition of toxin and Free-HA as 100%.
- Human colorectal cancer-derived cell line T84 cells are cultured using transwell (Coaster, 0.33 cm 2 ) and maintained for about 3 weeks to form tight junctions between cells and construct intestinal epithelial cell nore did. Tight junction formation was determined by measuring the intercellular electrical resistance (TER). In this experimental system, it was reported that tight junctions were formed sufficiently when 800 ⁇ 'cm 2 or more (Journal of Clinical Investigation, 104, 903-111, 1999), wells that showed a TER of 800 ⁇ 'cm 2 or higher were used in the experiment.
- TER intercellular electrical resistance
- botulinum type B 16S toxin was added at a final concentration of 50 nM. Then, in the CO incubator at 37 ° C, in Figure 4
- 7S toxin is a huge protein with a molecular weight of 150 kDa, it can be considered that it can pass through the noria of epithelial cells by this route, such as a protein preparation with the same or lower molecular weight.
- Human colorectal cancer-derived cell line T84 cells are cultured using transwell (Coaster, 4.7 cm 2 ) and maintained for about 3 weeks to form tight junctions between cells to construct intestinal epithelial cell noria did. Tight junction formation was determined by measuring the intercellular electrical resistance (TER). In this experimental system, it is reported that when the resistance is 400 ⁇ 'cm 2 or more, a tight junction is sufficiently formed and a cell barrier is constructed (Journal of Clinical Investigation, 1988, 82, 1516- 1524) Therefore, wells with a TER of 400 ⁇ -cm 2 or higher were used in the experiment. The TER value was measured using MilliceU-ERS (Millipore).
- Botulinum type B HA was added from the basolateral side of the cells to a final concentration of 50 nM. After culturing the cells for 21 hours in a 37 ° C CO incubator
- FITC-dextran with various molecular weights was added from the apical side. Four hours later, the basolateral medium was collected, and the amount of FITC-dextran was quantified by its fluorescence intensity. Negative control is the case where HA is not added.
- Botulinum B 16S addition suppresses cell barrier function of T84 cells and enhances barrier vortex of luteumum red
- Human colorectal cancer-derived cell line T84 cells were cultured using transwell (Coaster, 4.7 cm 2 ) and maintained for about 3 weeks to form tight junctions between cells to construct intestinal epithelial cell noria . Tight junction formation was determined by measuring the intercellular electrical resistance (TER). In this experimental system, it is reported that when the resistance is 400 ⁇ 'cm 2 or more, a tight junction is sufficiently formed and a cell barrier is constructed (Journal of Clinical Investigation, 1988, 82, 1516- 1524) Therefore, wells with a TER of 400 ⁇ -cm 2 or higher were used in the experiment. The TER value was measured using MilliceU-ERS (Millipore).
- Botulinum type B 16S was added from the basolateral side of the cells so that the final concentration was ⁇ . The cells were then cultured for 23 hours in a 37 ° C CO incubator.
- ruthenium red molecular weight 858.42
- ruthenium red molecular weight 858.42
- FIGS. 6A and 6B The results of this experiment are shown in FIGS. 6A and 6B.
- ruthenium red is present only on the apical side plasma membrane, but botulinum B type 16S supplementation of b in Fig. 6A and c in Fig. 6B. If hesitated, ruthenium red is apical From the side, it goes beyond the tight junction and becomes localized on the lateral side.
- botulinum type B nontoxic component labeled with Alexa-568 was added to a final concentration of 50 nM.
- This botulinum type B nontoxic component is a non-toxic component of the non-toxic component that dissociates from B-type 16S toxin at pH 8.0, and is a complex of NTNH and HA, Infection and Immunity, Mar. 2003, 1599 It is purified by the method described in -1603.
- the cells were cultured for 5 hours in a 37 ° C CO incubator, and the cells were paraformated.
- FIG. 7 After fixing with aldehyde, the cross section of the cells was observed with a confocal microscope (1000 times). The result is shown in FIG. The cell part is visualized by staining actin with phalloidin Alexa 488. As can be seen from FIG. 7, it was observed that Alexa 568-B type 16 nontoxic component was taken up into cells.
- Botulinum A 3 ⁇ 4 ⁇ HA positive progenitor toxin activity
- Human colorectal cancer-derived cell line T84 cells were cultured using transwell (Coaster, 4.7 cm 2 ) and maintained for about 3 weeks to form tight junctions between cells. Noria was built. Tight junction formation was determined by measuring the intercellular electrical resistance (TER). In this experimental system, it is reported that when the resistance is 400 ⁇ 'cm 2 or more, a tight junction is sufficiently formed and a cell barrier is constructed (Journal of Clinical Investigation, 1988, 82, 1516- 1524) Therefore, wells with a TER of 400 ⁇ -cm 2 or higher were used in the experiment. The TER value was measured using MilliceU-ERS (Millipore).
- Type A HA positive progenitor toxin is a mixture of 16S toxin and 19S toxin among 12S toxin, 16S toxin and 19S toxin produced by type A bacteria, and is purified by a known method (Infectio and Immunity, May 1996, 1589-1594).
- the electrical resistance was measured. The value obtained by subtracting the electrical resistance value of wells without cells was calculated and used as TER at that time. The results are shown in FIG. The vertical axis shows the TER value at each time in%, where the TER value just before the addition of the poison is 100%.
- the type A HA positive progenitor toxin (16S + 19S toxin) showed a clear decrease in TER after 24 hours, similar to the case where the type B 16S toxin was added. From the above, it was clarified that not only the B type 16S toxin but also the A type HA positive progenitor toxin has the action of reducing the tight junction function of T84 cells and eliminating the barrier between cells. Furthermore, since this activity of type A HA positive progenitor toxin is not present in type A 12S toxin, it is considered to be in type A HA.
- NTNH, HA and Free-HA in 16S toxin or a substance having a part of their amino acid sequence decreases the barrier function of epithelial cells and causes the drug to cross the epithelial cell barrier. It has become clear that it has a function of delivering it to the body and a function of transporting a drug to epithelial cells in the living body. Therefore, it has been clarified that the components derived from Clostridium botulinum such as NTNH, HA, and Free-HA in 16S toxin have a function of delivering drugs such as proteins into the body or a function of transporting them into cells.
- Clostridium-derived components such as Clostridium Botulinum neurotoxin complex produced by Clostridium botulinum, hemagglutinating active substance, or these components can reduce the barrier function of epithelial cells in the body and deliver the drug across the epithelial cell barrier to the body.
- Clostridium-derived components such as Clostridium Botulinum neurotoxin complex produced by Clostridium botulinum, hemagglutinating active substance, or these components can reduce the barrier function of epithelial cells in the body and deliver the drug across the epithelial cell barrier to the body.
- Clostridium-derived components such as Clostridium Botulinum neurotoxin complex produced by Clostridium botulinum, hemagglutinating active substance, or these components can reduce the barrier function of epithelial cells in the body and deliver the drug across the epithelial cell barrier to the body.
- FIG. 1 shows a fractionation profile when protein components in the culture supernatant of Clostridium botulinum type B lamanna strain are fractionated by cation exchange chromatography.
- Fig. 2 shows the free-HA fraction obtained by fractionating the protein components in the culture supernatant of Clostridium botulinum type B lamanna strain by cation exchange chromatography and then by affinity chromatography. The result of SDS-PAGE is shown.
- Fig. 3 shows the results when botulinum B type 16S toxin, B type 7S toxin, and B type Free-HA were added from the apical side of human colon cancer cell line T84 cells with tight junctions. The ratio of the electrical resistance value is shown.
- Fig. 4 shows the components that migrated to the basolateral side of cells after adding botulinum type B 16S toxin from the apical side of human colon cancer cell line T84 cells with tight junctions. Shows the results.
- NTNH is nontoxic non-HA
- Hc + Lc is 7S toxin heavy and light chain
- He is 7S toxin heavy chain
- Lc is 7S toxin light chain
- HA3b is one of the HA subcomponents. Indicates.
- FIG. 5 shows botulinum type B HA added from the basolateral side of human colon cancer-derived cell line T84 cells with tight junctions. After culturing the cells, FITC- The results of measuring the amount of FITC-dextran transferred from the apical side to the basolateral side after adding dextran from the apical side are shown.
- FIG. 6A shows that botulinum type B 16S was added from the basolateral side of human colon cancer cell line T84 cells with tight junctions, and the cells were cultured, and then lute-umred was introduced from the apical side. Luteu, who moved from apical to basolateral The result of having observed mured is shown.
- Fig. 6B shows that botulinum B type 16S was added from the basolateral side of human colon cancer cell line T84 cells with tight junctions, and the cells were cultured, and then lute-umred was introduced from the apical side. The result of observation of the luteum red that was transferred from the apical side to the basolateral side is shown.
- FIG. 7 shows that a botulinum type B nontoxic component added from the apical side of the human colon cancer-derived cell line caco2 cells having tight junctions is incorporated into Caco2 cells.
- Fig. 8 shows the case where botulinum type A HA positive progenitor toxin (16S + 19S toxin) is added from the apical side of human colon cancer cell line T84 cells with tight junctions.
- botulinum type A HA positive progenitor toxin (16S + 19S toxin) is added from the apical side of human colon cancer cell line T84 cells with tight junctions.
- type 16S toxin it shows that the human colon cancer-derived cell line T84 cells have the action of reducing the tight junction function and eliminating the barrier between cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003201776A JP2007070225A (ja) | 2003-07-25 | 2003-07-25 | クロストリジウム属菌由来成分を含む医薬製剤 |
JP2003-201776 | 2003-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005009475A1 true WO2005009475A1 (ja) | 2005-02-03 |
Family
ID=34100524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/010395 WO2005009475A1 (ja) | 2003-07-25 | 2004-07-22 | クロストリジウム属菌由来成分を含む医薬製剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2007070225A (ja) |
WO (1) | WO2005009475A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006010360A2 (de) * | 2004-07-22 | 2006-02-02 | Biotecon Therapeutics Gmbh | Carrier für arzneimittel zur gewinnung der oralen bioverfügbarkeit |
JP2009081997A (ja) * | 2007-09-27 | 2009-04-23 | Chemo Sero Therapeut Res Inst | ボツリヌス毒素成分haを核酸の細胞内導入キャリアーとして利用する方法 |
US7989169B2 (en) | 2004-09-03 | 2011-08-02 | Roche Molecular Systems, Inc. | Selective amplification of methylated nucleic acids |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2121025T3 (en) * | 2007-01-19 | 2017-01-30 | Hananja Ehf | Methods and compositions for delivering a therapeutic agent |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10500988A (ja) * | 1994-05-31 | 1998-01-27 | アレルガン インコーポレイテッド | 輸送タンパク質用クロストリジウム属細菌毒素の修飾 |
JP2001514316A (ja) * | 1997-08-29 | 2001-09-11 | バイオテック・オーストラリア・ピーティーワイ・リミテッド | 架橋粒子 |
WO2002005844A2 (de) * | 2000-07-19 | 2002-01-24 | BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH | Proteinkomplex als vehikel für oral verfügbare arzneimittel |
WO2002051429A2 (de) * | 2000-12-22 | 2002-07-04 | Migragen Ag | Verwendung einer zusammensetzung zur stimulation des nervenwachstums, zur inhibition der narbengewebsbildung, zur reduktion eines sekundärschadens und/oder zur akkumulation von makrophagen |
JP2003522199A (ja) * | 1999-12-02 | 2003-07-22 | マイクロバイオロジカル リサーチ オーソリティ | 神経細胞への治療薬の送達のための構築物 |
-
2003
- 2003-07-25 JP JP2003201776A patent/JP2007070225A/ja active Pending
-
2004
- 2004-07-22 WO PCT/JP2004/010395 patent/WO2005009475A1/ja not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10500988A (ja) * | 1994-05-31 | 1998-01-27 | アレルガン インコーポレイテッド | 輸送タンパク質用クロストリジウム属細菌毒素の修飾 |
JP2001514316A (ja) * | 1997-08-29 | 2001-09-11 | バイオテック・オーストラリア・ピーティーワイ・リミテッド | 架橋粒子 |
JP2003522199A (ja) * | 1999-12-02 | 2003-07-22 | マイクロバイオロジカル リサーチ オーソリティ | 神経細胞への治療薬の送達のための構築物 |
WO2002005844A2 (de) * | 2000-07-19 | 2002-01-24 | BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH | Proteinkomplex als vehikel für oral verfügbare arzneimittel |
WO2002051429A2 (de) * | 2000-12-22 | 2002-07-04 | Migragen Ag | Verwendung einer zusammensetzung zur stimulation des nervenwachstums, zur inhibition der narbengewebsbildung, zur reduktion eines sekundärschadens und/oder zur akkumulation von makrophagen |
Non-Patent Citations (5)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006010360A2 (de) * | 2004-07-22 | 2006-02-02 | Biotecon Therapeutics Gmbh | Carrier für arzneimittel zur gewinnung der oralen bioverfügbarkeit |
WO2006010360A3 (de) * | 2004-07-22 | 2007-12-27 | Biotecon Therapeutics Gmbh | Carrier für arzneimittel zur gewinnung der oralen bioverfügbarkeit |
US7989169B2 (en) | 2004-09-03 | 2011-08-02 | Roche Molecular Systems, Inc. | Selective amplification of methylated nucleic acids |
JP2009081997A (ja) * | 2007-09-27 | 2009-04-23 | Chemo Sero Therapeut Res Inst | ボツリヌス毒素成分haを核酸の細胞内導入キャリアーとして利用する方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2007070225A (ja) | 2007-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2376193C (en) | Therapeutic agent comprising a botulinum neurotoxin | |
AU2009203529B2 (en) | Methods and compositions for oral administration of protein and peptide therapeutic agents | |
Choi et al. | The effect of epidermal growth factor (EGF) conjugated with low-molecular-weight protamine (LMWP) on wound healing of the skin | |
Akash et al. | Development of therapeutic proteins: advances and challenges | |
JP7475276B2 (ja) | Fgf21バリアント、融合タンパク質及びそれらの適用 | |
KR100822006B1 (ko) | 경구적으로 투여가능한 약제의 전파체로서 작용하는단백질 복합체 | |
IE904292A1 (en) | Pharmaceutical for subcutaneous administration containing polypeptides | |
Yu et al. | Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA | |
KR20220005446A (ko) | 리포좀의 생산 방법 | |
Gjetting et al. | Effective Nanoparticle‐based Gene Delivery by a Protease Triggered Charge Switch | |
Li et al. | Ionic liquids: momentous tools in transdermal delivery of biomacromolecules | |
WO2005009475A1 (ja) | クロストリジウム属菌由来成分を含む医薬製剤 | |
CA2574124A1 (en) | Carrier for medicaments for obtaining oral bioavailability | |
JP2020515648A (ja) | リポソーム組成物及びそれを含む固体経口剤形 | |
Hwang et al. | Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex | |
Takahashi et al. | Peptides as tight junction modulators | |
JP2688603B2 (ja) | 血栓溶解剤 | |
EP4261230A1 (en) | Recombinant human serum albumin-collagen binding domain fusion protein for tumor-specific targeting matrix and application thereof | |
JP4006058B2 (ja) | 多臓器不全予防及び/又は治療剤 | |
CN103656665A (zh) | 抗肿瘤药物复合物及其制备方法 | |
CN105477628B (zh) | 抗癌组合物及其用途 | |
Bennett | Ocular delivery of proteins and peptides | |
WO2021129779A1 (zh) | 一种新型两亲性蛋白、其制备方法及用途 | |
Dan | An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins | |
WO2023037320A1 (en) | Mucosal messenger rna vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 06.04.06 AND 18.05.06) |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |